Search
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalIt was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.
Black cohosh
go.drugbank.com/drugs/DB13975ApprovedNative Americans used it for its purported benefits in treating musculoskeletal pain, fever, cough, pneumonia, sluggish labor, and menstrual irregularities.
Camostat
go.drugbank.com/drugs/DB13729Investigational[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.
ISA101b
go.drugbank.com/drugs/DB18694InvestigationalISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.
Acadesine
go.drugbank.com/drugs/DB04944InvestigationalIt is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
Dehydroascorbic acid
go.drugbank.com/drugs/DB08830ExperimentalDehydroascorbic acid is made from the oxidation of ascorbic acid. This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid. Dehydroascorbic acid as well as ascorbic acid ...
CD68-ET3-LV
go.drugbank.com/drugs/DB32864InvestigationalCD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.
VB10.16
go.drugbank.com/drugs/DB17512InvestigationalIt is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting
Tipifarnib
go.drugbank.com/drugs/DB04960InvestigationalIt belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
Periciazine
go.drugbank.com/drugs/DB01608ApprovedIt is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. … It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness.